Status:
UNKNOWN
Prevalence of Amyloidosis in Heart Failure (PREVAMIC)
Lead Sponsor:
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Conditions:
Heart Failure
Eligibility:
All Genders
65+ years
Brief Summary
TITLE: Study of Prevalence of Amyloidosis in Heart Failure: PREVAMIC. DESIGN: Multicenter, observational, cross-sectional, prospective, cohort study with a one-year follow-up. 44 hospitals from Spain...
Detailed Description
STUDY DESIGN AND PATIENT SELECTION DESIGN Multicenter, observational, cross-sectional, prospective, cohort study with a one-year follow-up. Approximately 450 patients will be gathered (according to ...
Eligibility Criteria
Inclusion
- Age ≥ 65 years.
- Both genders
- Heart failure outpatients or inpatients of Internal Medicine Services.
- Heart Failure (Criteria of HF European Guide 2016)
- Symptoms of HF
- NYHA class II to IV
- Echocardiogram performed in the previous 24 months
- FEVI: any value
- HVI: Septum or Posterior Wall \> 12 mm
- Diuretic treatment in the last 6 months
- NTproBNP \> 1800 or BNP \> 400 during any hospital admission, or NTproBNP \> 600 or BNP \> 150 in a stable situation.
Exclusion
- Patients with cancer disease (solid tumor)
- Patients who are included in other studies or clinical trial
- Refusal of patients to participate
Key Trial Info
Start Date :
February 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2021
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT04066452
Start Date
February 3 2020
End Date
September 1 2021
Last Update
March 5 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Universitario Virgen Macarena
Seville, Spain, 41071